ATRA — Atara Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $46.62m
- $45.38m
- $128.94m
- 28
- 51
- 80
- 53
Annual cashflow statement for Atara Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -307 | -340 | -228 | -276 | -85.4 |
| Depreciation | |||||
| Non-Cash Items | 53.8 | 57.7 | 13.7 | 63 | 42.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 63.7 | 52.6 | -61.5 | 15.3 | -31 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -181 | -221 | -270 | -193 | -68.7 |
| Capital Expenditures | -4.51 | -10.6 | -4.19 | -1.22 | -0.246 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -116 | 32.8 | 207 | 125 | 8.87 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -121 | 22.3 | 203 | 124 | 8.62 |
| Financing Cash Flow Items | 4.99 | 5.5 | 31.7 | 0.821 | 0.223 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 428 | 104 | 53.1 | 2.01 | 59.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 126 | -94.3 | -14.4 | -67.1 | -0.811 |